(Q37822778)

23 August 2017

1 reference

title

If at first you don't succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies (English)

1 reference

23 August 2017

K Ryan Connolly

1

1 reference

PubMed ID

21175239

23 August 2017

Michael E Thase

series ordinal

2

1 reference

23 August 2017

1 January 2011

1 reference

23 August 2017

1 reference

23 August 2017

71

1 reference

23 August 2017

1

1 reference

23 August 2017

43-64

1 reference

https://scigraph.springernature.com/pub.10.2165/11587620-000000000-00000

23 August 2017

0 references

cites work

Posttraumatic stress disorder in the National Comorbidity Survey

1 reference

https://api.crossref.org/works/10.2165%2F11587620-000000000-00000

Lithium carbonate: a clinical study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587620-000000000-00000

Lithium carbonate addition in tricyclic antidepressant-resistant unipolar depression. Correlations with the neurobiologic actions of tricyclic antidepressant drugs and lithium ion on the serotonin system.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587620-000000000-00000

Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587620-000000000-00000

Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587620-000000000-00000

Risperidone for treatment-refractory major depressive disorder: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587620-000000000-00000

Pindolol and mianserin augment the antidepressant activity of fluoxetine in hospitalized major depressed patients, including those with treatment resistance.

21 January 2018

1 reference

12 December 2020

Modafinil augmentation of selective serotonin reuptake inhibitor therapy in MDD partial responders with persistent fatigue and sleepiness

1 reference

12 December 2020

A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression

1 reference

12 December 2020

A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder.

1 reference

12 December 2020

Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study

1 reference

12 December 2020

Use of atypical antipsychotics in refractory depression and anxiety.

1 reference

12 December 2020

Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance.

1 reference

12 December 2020

Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.

1 reference

12 December 2020

Osmotic-release oral system methylphenidate augmentation of antidepressant monotherapy in major depressive disorder: results of a double-blind, randomized, placebo-controlled trial.

1 reference

12 December 2020

Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study.

1 reference

12 December 2020

Switching to duloxetine in selective serotonin reuptake inhibitor non- and partial-responders: effects on painful physical symptoms of depression

1 reference

12 December 2020

A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report

1 reference

12 December 2020

Psychostimulants for depression

1 reference

12 December 2020

Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder

1 reference

12 December 2020

Venlafaxine and paroxetine in treatment-resistant depression. Double-blind, randomised comparison.

1 reference

12 December 2020

Prevalence and outcome of partial remission in depression

1 reference

12 December 2020

Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy.

1 reference

12 December 2020

Diagnosis and definition of treatment-resistant depression

1 reference

12 December 2020

A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder

1 reference

12 December 2020

Benefits from mianserin augmentation of fluoxetine in patients with major depression non-responders to fluoxetine alone

1 reference

12 December 2020

Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study.

1 reference

12 December 2020

A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression

1 reference

12 December 2020

Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled st

1 reference

12 December 2020

Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study

1 reference

12 December 2020

Depression in the medically ill: diagnostic and therapeutic implications

1 reference

12 December 2020

Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study.

1 reference

12 December 2020

Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants

1 reference

12 December 2020

A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness.

1 reference

12 December 2020

Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report.

1 reference

12 December 2020

The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study.

1 reference

12 December 2020

Lithium Augmentation of Nortriptyline for Subjects Resistant to Multiple Antidepressants

1 reference

12 December 2020

Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor

1 reference

12 December 2020

Refractory depression: the addition of lithium to fluoxetine or desipramine.

1 reference

12 December 2020

Lithium augmentation therapy in tricyclic-resistant depression. A controlled trial using lithium in low and normal doses.

1 reference

12 December 2020

Clinical practice recommendations for depression

1 reference

12 December 2020

Does thyroid supplementation accelerate tricyclic antidepressant response? A review and meta-analysis of the literature

1 reference

12 December 2020

Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report.

1 reference

12 December 2020

Lithium augmentation in treatment-resistant depression: clinical evidence, serotonergic and endocrine mechanisms

1 reference

12 December 2020

Lithium and triiodothyronine augmentation of antidepressants.

1 reference

12 December 2020

Treatment of imipramine-resistant recurrent depression, III: Efficacy of monoamine oxidase inhibitors

1 reference

12 December 2020

Efficacy of fluvoxamine in treatment-refractory depression.

1 reference

12 December 2020

Combined treatment with sertraline and liothyronine in major depression: a randomized, double-blind, placebo-controlled trial

1 reference

12 December 2020

Modafinil: a review of neurochemical actions and effects on cognition

1 reference

12 December 2020

Lithium augmentation in treatment-resistant depression: meta-analysis of placebo-controlled studies

1 reference

12 December 2020

Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors

1 reference

12 December 2020

Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials.

1 reference

12 December 2020

Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs

1 reference

12 December 2020

Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis

1 reference

12 December 2020

A randomized, double-blind, placebo-controlled trial of buspirone in combination with an SSRI in patients with treatment-refractory depression

1 reference

12 December 2020

Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice.

1 reference

12 December 2020

Medication augmentation after the failure of SSRIs for depression.

1 reference

12 December 2020

Nortriptyline for treatment-resistant depression.

1 reference

12 December 2020

The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysis

1 reference

12 December 2020

Efficacy and safety of triiodothyronine supplementation in patients with major depressive disorder treated with specific serotonin reuptake inhibitors

1 reference

12 December 2020

Dose-dependent influence of buspirone on the activities of selective serotonin reuptake inhibitors in the mouse forced swimming test

1 reference

12 December 2020

Treatment of tricyclic refractory depression with a monoamine oxidase inhibitor antidepressant

1 reference

12 December 2020

The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study

1 reference

12 December 2020

Effects of risperidone augmentation in patients with treatment-resistant depression: Results of open-label treatment followed by double-blind continuation

1 reference

12 December 2020

Examining the efficacy of adjunctive aripiprazole in major depressive disorder: a pooled analysis of 2 studies

1 reference

12 December 2020

A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: a clinical, pharmacokinetic, and pharmacogenetic investigation

1 reference

12 December 2020

Pharmacological principles of antidepressant efficacy

1 reference

12 December 2020

Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation

1 reference

12 December 2020

A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression.

1 reference

12 December 2020

A novel augmentation strategy for treating resistant major depression

1 reference

12 December 2020

Revisiting monoamine oxidase inhibitors.

1 reference

12 December 2020

Efficacy and tolerability of adjunctive ziprasidone in treatment-resistant depression: a randomized, open-label, pilot study

1 reference

12 December 2020

A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report

1 reference

12 December 2020

Effectiveness of pindolol plus serotonin uptake inhibitors in depression: a meta-analysis of early and late outcomes from randomised controlled trials

1 reference

12 December 2020

Venlafaxine extended release versus conventional antidepressants in the remission of depressive disorders after previous antidepressant failure: ARGOS study

1 reference

12 December 2020

A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine

1 reference

12 December 2020

Enhancement of imipramine antidepressant activity by thyroid hormone

1 reference

12 December 2020

Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression

1 reference

12 December 2020

Use of atypical antipsychotics for treatment-resistant major depressive disorder

1 reference

12 December 2020

The co-administration of quetiapine or placebo to cognitive-behavior therapy in treatment refractory depression: a preliminary trial

1 reference

12 December 2020

A Comparison of Mirtazapine and Nortriptyline Following Two Consecutive Failed Medication Treatments for Depressed Outpatients: A STAR*D Report

1 reference

12 December 2020

10.2165/11587620-000000000-00000

Identifiers

DOI

1 reference

PubMed ID

21175239

Dimensions Publication ID

23 August 2017

0 references

1 reference

PubMed ID

21175239